Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi has recently teamed up with Regeneron to make a new cholesterol drug that could reduce risk for heart attack in half by targeting the PCSK9 protein. They are in direct competition with Amgen to make the drug and then test it and then be the first to release it to the public. Amgen was first to the punch as they recently filed their product—evolocumab—with regulators for sale in the United States.
Sanfoi and Regeneron’s new experimental drug—alirocumab—has been part of a long term, 2,341-patient study that the team hopes to conclude early next year. The Odyssey Long Term study, so far, has yielded impressively promising results, which actually leads many of the researchers to be more cautious than celebratory. President of the American College of Cardiology Patrick O’Gara of Boston’s Brigham and Women’s Hospital said that the post-hoc nature of this conclusion merits caution. More accurately, he said “It’s so much wished-for that we must be careful.”
http://diabetesinsider.com/sanofi-regeneron-set-release-hopeful-cholesterol-medication/35178
Sanfoi and Regeneron’s new experimental drug—alirocumab—has been part of a long term, 2,341-patient study that the team hopes to conclude early next year. The Odyssey Long Term study, so far, has yielded impressively promising results, which actually leads many of the researchers to be more cautious than celebratory. President of the American College of Cardiology Patrick O’Gara of Boston’s Brigham and Women’s Hospital said that the post-hoc nature of this conclusion merits caution. More accurately, he said “It’s so much wished-for that we must be careful.”
http://diabetesinsider.com/sanofi-regeneron-set-release-hopeful-cholesterol-medication/35178